ASCO 2020 - Wrap Up

Results from the ARROW study show that pralsetinib demonstrates broad and durable antitumor activity across multiple advanced solid tumor types, regardless of RET fusion genotype.
Results from the ARROW study showed that pralsetinib has rapid, potent, and durable clinical activity in patients with advanced RET fusion–positive non–small-cell lung cancer, regardless of RET fusion genotype or prior therapies.
The AcceleRET Lung study will evaluate the efficacy and safety of pralsetinib compared with standard of care for first-line treatment of patients with advanced/metastatic RET fusion–positive non–small-cell lung cancer.
Results from the phase 2 GEOMETRY mono-1 study confirm capmatinib to be efficacious in second-line treatment of patients with MET exon 14–mutated non–small-cell lung cancer.
An updated analysis of 3 phase 1/2 trials finds that entrectinib continues to demonstrate clinically meaningful responses in patients with NTRK fusion–positive solid tumors, including those with and without baseline central nervous system disease.
The next-generation RET inhibitor TPX-0046 demonstrates potent in vitro and in vivo activity against a diverse range of RET alterations, including solvent front mutation–mediated resistance.
Selpercatinib (LOXO-292) use was associated with durable antitumor activity in patients with RET-mutant medullary thyroid cancer previously treated with cabozantinib and/or vandetanib as well as in cabozantinib/vandetanib-naïve patients.
In newly diagnosed patients with lung cancer, liquid biopsy using the Guardant 360 assay identifies actionable targets beyond those identified by tumor tissue profiling alone and with a shorter turnaround time.
Results from the CHRYSALIS study show that amivantamab demonstrates robust and durable antitumor activity and a manageable safety profile in patients with EGFR exon20ins-mutated non–small-cell lung cancer.
A substantial minority of patients with advanced non–small-cell lung cancer and highly actionable gene variants were not prescribed available targeted therapies in the Veterans Health Affairs National Precision Oncology Program.

Results 1 - 10 of 10